Elevance Health, Inc.
336.36-3.04 (-0.9%)
Oct 29, 4:00:02 PM EDT · NYSE · ELV · USD
Report date
≈ Jan 22, 2026 (in 84 days)EPS
11.06 (9.27 ~ 13.99)Revenue
50.90B (49.27B ~ 51.84B)Key Stats
Market Cap
74.75BP/E (TTM)
13.70Basic EPS (TTM)
24.55Dividend Yield
0.02%Recent Filings
8-K
Q3 revenue up 12%, costs rise
Elevance Health posted third-quarter 2025 operating revenue of $50.1 billion, up 12% from last year, fueled by premium growth and acquisitions, yet adjusted operating gain dipped to $1.3 billion amid Medicare cost pressures from Inflation Reduction Act changes. Benefit expense ratio climbed to 91.3%, while membership held at 45.4 million despite Medicaid losses. Revenue surged. The company reaffirmed its full-year adjusted EPS guidance at $30.00, underscoring steady capital returns of $3.3 billion year-to-date.
10-Q
Q3 FY2025 results
Elevance Health posted solid Q3 results, with operating revenue climbing 12.0% year-over-year to $50.1B, fueled by premium rate hikes across Health Benefits and Medicare Advantage membership growth, though Medicaid attrition tempered gains. Premiums surged 13.5% y/y to $41.8B, while the benefit ratio edged up to 91.3% from 89.5% amid elevated Medicare and commercial trends; operating income dipped 8.0% y/y to $1.3B, but diluted EPS jumped 22.0% to $5.32 on fewer shares and lighter tax hits. YTD, revenue rose 13.9% to $148.3B with EPS at $22.67, down 4.8% y/y, reflecting Health Benefits pressures offset by CarelonRx and Services gains. Cash swelled to $8.7B, bolstered by $4.2B operating flow, while total debt hit $31.9B after fresh notes issuance; free cash flow stood at $3.4B (derived). December 2024's CareBridge buy added $1.8B goodwill and $305M intangibles (amortized over undisclosed lives), enhancing home-based Medicaid care. Solid balance sheet shines. Yet antitrust suits linger as a key risk.
8-K
Elevance Health closes $3B notes
Elevance Health closed a $3 billion notes offering on September 15, 2025, issuing $750 million of 4.000% notes due 2028, $750 million of 4.600% notes due 2032, $1 billion of 5.000% notes due 2036, and $500 million of 5.700% notes due 2055. Net proceeds of $2,972.7 million will repay $400 million 5.350% notes due 2025 and $500 million 4.900% notes due 2026, with the rest for working capital, acquisitions, debt repayment, and stock repurchases. This refinancing extends maturities while locking in lower rates. Redemption options add flexibility, but change-of-control triggers a 101% buyback.
8-K
Reaffirms 2025 earnings guidance
Elevance Health officers will reaffirm 2025 earnings guidance in upcoming investor meetings, projecting $24.10 per diluted share including $5.90 in net unfavorable items, with adjusted earnings at $30.00 per share. They also expect a 90.0% benefit expense ratio, reflecting current market conditions and operational views. Guidance holds steady. Yet actual results may differ if business assumptions shift.
8-K
Elevance Health adds board director
Elevance Health's board elected Steven H. Collis, Executive Chairman of Cencora, as an independent director effective August 1, 2025, appointing him to the Audit and Finance Committees. Collis, with decades in healthcare supply chain leadership, qualifies as an audit committee financial expert, bolstering financial oversight. This move refreshes the board to align with strategic goals in a shifting healthcare market. His expertise sharpens governance amid industry changes.
IPO
Employees
Sector
Industry
CI
The Cigna Group
299.12-9.29
CLOV
Clover Health Investments, Corp
3.64-0.12
CNC
Centene Corporation
37.34+4.15
CTEV
Claritev Corporation
68.60-2.58
CVS
CVS Health Corporation
80.60-1.60
EHTH
eHealth, Inc.
5.46-0.19
EVH
Evolent Health, Inc
7.08-0.33
HUM
Humana Inc.
292.67-2.13
NEUE
NeueHealth, Inc.
6.75+0.00
UNH
UnitedHealth Group Incorporated
355.26-12.58